MedTrace Logo

Rosuvastatin Effect on Telomere-telomerase System in ACS

NCT02299245 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2015-07-14

No results posted yet for this study

Summary

Coronary heart disease (CHD) is one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. The mean telomere length and telomerase activity serve as markers for the biological age at the cellular level, with shorter telomeres and lower telomerase activity defining the increased biological age. Telomere length and telomerase activity, therefore, correlates with the risk of CHD and atherosclerosis. A present study states that the treatment with a statin is associated with a reduction in the number of clinical events but only in individuals with increased risk based on their telomere length. This suggests a positive relationship of telomere and telomerase system with the treatment with statins in CHD patients.

Conditions

  • Telomere Shortening
  • Telomere Length, Mean Leukocyte
  • 22q Telomere Deletion Syndrome

Interventions

DRUG

rosuvastatin

different dose of rosuvastatin treatment

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Xiao-dong Zhuang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-07-31
Completion
2016-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02299245 on ClinicalTrials.gov